Nasdaq
$2.28▼ 0.22%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $249.0MShares out 1.100M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
24- 10.6After-hours26.10.07 06:158-KKey event#●●●#●●●#●●●
ROCKET PHARMACEUTICALS, INC.
Rocket Pharmaceuticals has entered into a senior secured term loan agreement with Hercules Capital for up to $150 million. The company received $35 million at closing and may access the remaining funds upon achieving clinical and regulatory milestones, extending its cash runway into the third quarter of 2028. Additionally, the company issued warrants to purchase up to 1,755,853 shares of its common stock in connection with the financing.…more
$2.28-0.22%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.16Overnight26.09.16 09:274Ownership
ROCKET PHARMACEUTICALS, INC.
Insider Wilson Martin of Rocket Pharmaceuticals, Inc. reported a change in beneficial ownership of securities as of September 11, 2026. This filing serves to provide market transparency regarding the insider's equity holdings.…more
$2.28-0.22%vs prev closeView filingShare - 9.15After-hours26.09.16 05:50144Ownership
ROCKET PHARMACEUTICALS, INC.
John Militello, an insider at Rocket Pharmaceuticals, Inc., has filed an SEC Form 144 to report a proposed sale of company securities. This is a standard notification regarding the disposition of shares by an insider.…more
$2.28-0.22%vs prev closeView filingShare
23 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.7Regular26.10.07 22:45#●●●#●●●
Rocket Pharmaceuticals Shares Danon Disease Phase 2 Clinical Update
Rocket Pharmaceuticals reported key data and safety observations from its pivotal Phase 2 trial for Danon disease. The company outlined a clear path to trial completion following alignment with the FDA.…more
$2.28-0.22%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.6After-hours26.10.07 05:13
●●●●●●●● ●●●●● ●●●●●●
Rocket Pharmaceuticals has secured a credit facility of up to $150 million from Hercules Capital, with $35 million drawn at closing. This financing extends the company's cash runway through the third quarter of 2028.…more
$2.28-0.22%vs prev closeShareBenzinga - 9.15Pre-market26.09.15 20:12
●●●●●●●● ●●●●● ●●●●●●
Rocket Pharmaceuticals has reached an agreement with the FDA on the key elements and continued enrollment for its Phase 2 pivotal trial of RP-A501. The company aims to complete the 12-patient study by mid-2027 to support a potential accelerated approval pathway.…more
$2.28-0.22%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report